Company ProfileWe are the leading company in RNA-targeted drug discovery and development with a pipeline of first-in-class or best-in-class medicines with the potential to provide high value for patients with significant unmet medical needs. We have created an efficient and broadly applicable drug discovery platform. Using this platform, we believe that we are revolutionizing medicine with the goal to improve the quality of, and save, lives.
|Recent Press Releases||More >>|
|07/19/16||Ionis Pharmaceuticals Licenses First Oral Antisense Drug Acting Locally in the GI Tract to Janssen|
|CARLSBAD, Calif., July 19, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has earned $10 million from Janssen Biotech, Inc. (Janssen) upon licensing IONIS-JBI1-2.5Rx, an orally delivered antisense drug designed to locally inhibit an undisclosed target in the gastrointestinal (GI) tract for the treatment of a GI autoimmune disease. Janssen will assume all global development, regulatory and commercialization responsibilities for IONIS-JBI1-2.5Rx once Ionis... |
|07/12/16||Ionis Pharmaceuticals Announces Publication in Nature Biotechnology of a Novel Mechanism of Action for Antisense Drugs That Significantly Expands Therapeutic Opportunities|
|-Innovative New Mechanism Allows Antisense Drugs to Increase the Production of Specific Proteins By Up to 150%-
CARLSBAD, Calif., July 12, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the publication of new research findings in Nature Biotechnology describing a new mechanism of action for antisense technology, which further expands the potential reach of antisense technology. The paper entitled "Translation efficiency of mRNAs is increased by antisense olig... |
|07/07/16||Ionis Pharmaceuticals Reports Positive Clinical Data on IONIS-TTR Rx at the XV International Symposium on Amyloidosis|
|Evidence for disease stabilization observed in patients with TTR amyloid cardiomyopathy
Substantial reductions in both mutant and wild-type TTR protein observed in patients with familial amyloid polyneuropathy
CARLSBAD, Calif., July 7, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONIS) announced today positive results from two ongoing trials with IONIS-TTRRx:
An ongoing investigator-sponsored, open-label Phase 2 study in patients with TTR amyloid cardiomyopathy, w... |
|06/29/16||Akcea Therapeutics Announces Launch of IN-FOCUS, a Research Study to Assess Impact of Familial Chylomicronemia Syndrome|
|People affected by FCS invited to share their experience
CAMBRIDGE, Mass., June 29, 2016 /PRNewswire/ -- Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced the launch of the first-ever research study to understand the multi-dimensional impact of familial chylomicronemia syndrome (FCS) from the perspective of... |
|There are currently no events scheduled.|
For more information requests, please visit our Information Request page.
If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.
Data provided by Nasdaq. Minimum 15 minutes delayed.